FDA rejects Nastech's Miacalcin-like nasal spray

07/13/2006 | MSN Money

Nastech Pharmaceutical Co. announced the FDA did not approve its osteoporosis nasal spray, which is similar to Novartis' Miacalcin, due to concerns the combination of the preservative chlorobutanol and calcitonin-salmon could provoke an immune response. The company said it plans to hold discussions with the FDA and may explore other alternatives to gaining regulatory approval.

View Full Article in:

MSN Money

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA